» Articles » PMID: 29914181

Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2018 Jun 20
PMID 29914181
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant cells cultured in three-dimensional (3D) models have been found to be phenotypically and biochemically different from their counterparts cultured conventionally. Since most of these studies employed solid tumor types, how 3D culture affects multiple myeloma (MM) cells is not well understood. Here, we compared MM cells (U266 and RPMI8226) in a 3D culture model with those in conventional culture. While the conventionally cultured cells were present in single cells or small clusters, MM-3D cells grew in large spheroids. We discovered that STAT3 was the pathway that was more activated in 3D in both cell lines. The active form of STAT3 (phospho-STAT3 or pSTAT3), which was absent in MM cells cultured conventionally, became detectable after 1⁻2 days in 3D culture. This elevated pSTAT3 level was dependent on the 3D environment, since it disappeared after transferring to conventional culture. STAT3 inhibition using a pharmacological agent, Stattic, significantly decreased the cell viability of MM cells and sensitized them to bortezomib in 3D culture. Using an oligonucleotide array, we found that 3D culture significantly increased the expression of several known STAT3 downstream genes implicated in oncogenesis. Since most primary MM tumors are naturally STAT3-active, studies of MM in 3D culture can generate results that are more representative of the disease.

Citing Articles

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.

Poos A, Prokoph N, Przybilla M, Mallm J, Steiger S, Seufert I Blood. 2023; 142(19):1633-1646.

PMID: 37390336 PMC: 10733835. DOI: 10.1182/blood.2023019758.


Establishment of A Three-Dimensional Culture Condition for The U266 Cell Line Based on Peripheral Blood Plasma-Derived Fibrin Gels.

Jomehpour M, Khosravi M, Janfada M, Abroun S, Vahdat S Cell J. 2023; 25(4):229-237.

PMID: 37210643 PMC: 10201360. DOI: 10.22074/cellj.2023.562849.1138.


Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine-Are We There Yet?.

Lourenco D, Lopes R, Pestana C, Queiros A, Joao C, Carneiro E Int J Mol Sci. 2022; 23(21).

PMID: 36361677 PMC: 9657251. DOI: 10.3390/ijms232112888.


Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells.

Zhou L, Pei X, Zhang Y, Ning Y, Li L, Hu X Mol Cancer Res. 2021; 20(3):456-467.

PMID: 34782371 PMC: 8898301. DOI: 10.1158/1541-7786.MCR-21-0366.


Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism.

Huang Y, Almowaled M, Li J, Venner C, Sandhu I, Peters A Curr Issues Mol Biol. 2021; 43(1):313-323.

PMID: 34201211 PMC: 8928965. DOI: 10.3390/cimb43010026.


References
1.
Zhu J, Wang M, Cao B, Hou T, Mao X . Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma. Curr Med Chem. 2014; 21(27):3173-87. DOI: 10.2174/0929867321666140601204513. View

2.
Kolosenko I, Grander D, Tamm K . IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma. Curr Med Chem. 2014; 21(26):3042-7. DOI: 10.2174/0929867321666140414100831. View

3.
Tong A, Huang Y, Zhang B, Netto G, Vitetta E, Stone M . Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Anticancer Res. 1993; 13(3):593-7. View

4.
Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters R . Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2001; 95(8):2630-6. View

5.
Park M, Jeong H, Son S, Kim Y, Han D, Goughnour P . Novel Morphologic and Genetic Analysis of Cancer Cells in a 3D Microenvironment Identifies STAT3 as a Regulator of Tumor Permeability Barrier Function. Cancer Res. 2015; 76(5):1044-54. DOI: 10.1158/0008-5472.CAN-14-2611. View